Primary Objective: Following stroke, hypothermia is reported to reduce both cellular and extracellular damage. This study aimed to examine the effects of focal mild hypothermia on proteins associated with both extracellular (matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of MMP-9 (TIMP-1)) and cellular damage (Tau-1 and β-amyloid precursor protein (β-APP)) to characterize the protective effects of hypothermia.
Methods And Procedures: Male Wistar rats received ischaemic damage using a transient, focal ischaemia/reperfusion model. Afterwards, one group (HT) received 6 hours of focal mild hypothermia (33 °C) applied to the head, while another remained at normal temperature (NT). The brains were collected at 6, 12, 24, 48 and 72 hours after hypothermia to measure infarct volume ratio and to detect cells immunopositive for MMP-9, TIMP-1, Tau-1 and β-APP, while neurological deficits were examined separately after 2 weeks.
Main Outcomes And Results: Focal mild hypothermia had no effect on infarct volume ratio but expression of MMP-9, TIMP-1 Tau-1 and β-APP was decreased. Furthermore, neurological function in the HT group was better than in the NT group.
Conclusions: Focal mild hypothermia has protective effects on cerebral ischaemia-reperfusion injury characterized by decreased expression of MMP-9, TIMP-1, Tau-1 and β-APP, along with improvement of neurological function despite no changes in infarct volume.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/02699052.2013.804206 | DOI Listing |
Vaccines (Basel)
November 2024
Department of Infectious Diseases, National Institute of Health Doctor Ricardo Jorge, Public Health Centre Doutor Gonçalves Ferreira, Rua Alexandre Herculano 321, 4000-055 Porto, Portugal.
A vaccination programme against severe acute respiratory syndrome coronavirus 2 was initiated in Portugal in December 2020. In this study, we report the findings of a prospective cohort study implemented with the objective of monitoring antibody production in response to COVID-19 vaccination. The humoral immune response to vaccination was followed up using blood samples collected from 191 healthcare workers.
View Article and Find Full Text PDFVaccines (Basel)
November 2024
Department of Systems Biotechnology, Chung-Ang University, Anseong 17456, Republic of Korea.
Respiratory syncytial virus (RSV) causes symptoms similar to a mild cold for adults, but in case of infants, it causes bronchitis and/or pneumonia, and in some cases, mortality. Mucosal immunity within the respiratory tract includes tissue-resident memory T (T) cells and tissue-resident memory B (B) cells, which provides rapid and efficient protection against RSV re-infection. Therefore, vaccine strategies should aim to generate mucosal immune responses.
View Article and Find Full Text PDFJ Clin Med
December 2024
Department of Anesthesiology, Duke University Medical Center, DUMC 3094, Durham, NC 27710, USA.
: In 2021, the Food and Drug Administration approved liposomal bupivacaine injectable suspension for single-dose infiltration in patients ≥ 6 years of age. Liposomal bupivacaine and bupivacaine hydrochloride admixtures may also be administered off-label for pediatric regional anesthesia including peripheral nerve blocks (PNBs). This single-injection, long-acting technique is not well described in pediatrics but may have benefits over traditional continuous catheter-based systems.
View Article and Find Full Text PDFJ Clin Med
December 2024
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine, University of Augsburg, 86156 Augsburg, Germany.
: To analyze the results of interstitial (IRT) high-dose-rate (HDR) brachytherapy (BT) in the primary treatment of patients with unresectable superior sulcus tumors (SST) combined with external beam radiotherapy (EBRT). : Between 2013 and 2023, seven patients with unresectable SST were treated with combined BT and EBRT with or without concomitant chemotherapy. The patients' median age was 64 years (range, 49-79 years) and median tumor volume was 146.
View Article and Find Full Text PDFCancers (Basel)
December 2024
Radiation Oncology Department, Centre Leon Berard, 69373 Lyon, France.
Background: Radical prostatectomy (RP) is one possible curative treatment for localized prostate cancer. Despite that, up to 40% of patients will later relapse. Currently, post-operative radiotherapy (PORT) courses deliver 1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!